1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60ECD4450F8DF3F36852584820044282A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-value-driven-patient-support-programs-structure-effectiveness-resource-levels?opendocument
18
19opendocument
203.239.87.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Patient Focused Services » Patient Support Programs

Value-Driven Patient Support Programs: Structure, Effectiveness and Resource Levels

ID: 5581


Features:

4 Info Graphics

19 Data Graphics

290+ Metrics

1 Narratives


Pages/Slides: 31


Published: 2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Value-Driven Patient Support Programs: Structure, Effectiveness and Resource Levels”

STUDY OVERVIEW

"Value-driven" patient support goes beyond simply providing financial assistance for patients' medications. Today, leading pharma and biotech companies are taking rapid steps to implement a comprehensive patient support program to improve the lives of patients across numerous fronts.

Best Practices, LLC conducted this benchmarking research to better understand the growing importance of establishing a patient-centric organization and how it can positively impact patient outcomes and commercial results. This study delivers insights around patient support group structure, activities and resource/investment levels within the biopharmaceutical sector.

Patient support leaders can use this study to evaluate how their patient support programs compare against industry averages and trends.

KEY TOPICS

  • Patient Support Organizational Structure
  • Patient Support Group Effectiveness
  • Patient Support Group Budget
  • Patient Support Group Staffing
  • Funding Sources for Patient Support Group

KEY METRICS
  • Which of the listed metrics do you think are effective for measuring the success of your patient support activities?
  • Please estimate the percentage of your patients (to whom you target patient support) who are aware of your patient support activities and who take advantage of or engage in your patient support activities
  • What are best practices for the implementation of patient support programs in multiple countries?
  • Under what function does your patient support group work and report?
  • Please estimate the total budget for patient support initiatives, activities and programs during the current budget year for A) patient support services in your area of responsibility and B) total organizational spend
  • Please estimate the percentage your patient support budget represents of your company's total budget for patient service initiatives, activities, and programs during the current budget year
  • Please estimate your current capital budget for infrastructure (e.g. technology, service center capabilities, etc.) to support your patient support programs specifically dedicated for patient support
  • Which of the listed organizations provide funding for your patient support program?
  • How many FTEs (full time equivalent employees = in-house + contract) work in your company’s worldwide patient support organization?

SAMPLE KEY FINDINGS
  • Increase expenditure on patient treatment experience and patient adherence: Nearly three fourths of the respondents cited improving treatment experience of patients and patient adherence as highly influential drivers in designing patient support programs, followed by improving treatment experience of HCPs (68%) and helping patients improve quality of life (65%). Thus, it is necessary to direct most of the budget toward activities that are patient focused, such as understanding unmet patient needs.

METHODOLOGY

Best Practices, LLC engaged 57 Patient Support leaders from 41 pharmaceutical companies in this research through a primary benchmarking survey. Research analysts also conducted secondary research regarding the different platforms that companies are using to engage with patients. More than 70% of the benchmark partners serve at the director level or above.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Medical Device; Manufacturing; Biotech; Consumer Products; Diagnostic; Service; Chemical; Health Care; Communications; Research; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Baxter International; Bayer; Bionical Solutions; Boehringer Ingelheim; Celgene; Cipla; Daiichi Sankyo; Dr Reddy's Laboratories; EMD Serono; Envision Pharma Group; GlaxoSmithKline ; Hoffmann-La Roche; Horizon Pharma; Incyte; Invive Healthcare; Ipsen; Johnson & Johnson; Kadmon Pharmaceuticals; LEO Pharma; Merck; Merck Serono; MSD; Myovant Sciences; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parexel; Pfizer; S3 Group; Sanofi; Sanofi Genzyme; Servier; Takeda Oncology; Takeda Pharmaceuticals; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.